leisure time -WSS

leisure time

author：hotspot 2025-08-26 01:32:45 - browse：17251

Alphabet’s life sciences company Verily has scored its first Centers for Disease Control and Prevention contract, a high profile job leaders hope will boost its brand in public health as well as its nascent wastewater surveillance business, executives told STAT.

Under the up-to-five year, $38 million contract, Verily will collect samples from hundreds of wastewater treatment centers across the country, analyze them for Covid-19 and the mpox virus at its South San Francisco lab, and return the data to CDC within 36 hours of collecting the samples. The contract is limited to those two pathogens but the company is prepared to analyze more if needed, leaders said.

The contract comes as Verily struggles to turn a profit among various disparate health care offerings, like value-based care analytics for health systems, clinical trial software and even an in-person substance use rehabilitation center in Ohio. Despite several prominent hires and a vast number of projects, the company has yet to forge a sustainable business.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Letters to First Opinion on caregivers, digital health, and more

knowledge

WSS

How to increase colonoscopy rates? Looks like an AI can help

With trial win, GSK could get blood cancer drug back on market

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

ASCO: AstraZeneca says CAR

Shifting the focus from loneliness to social health

Shifting the focus from loneliness to social health

hotspot

leisure time

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

ASCO: AstraZeneca says CAR

Walensky prepares to leave CDC — and Congress — behind

NIH documents show early flaws of $1.6 billion long Covid program

Sports medicine is finally prioritizing gender equality

Ultragenyx gene therapy for rare liver ailment succeeds in late

Medicare proposal to cover medical devices draws a mixed reaction

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Jerome Adams on the need for new antivirals for Covid

NIH documents show early flaws of $1.6 billion long Covid program

leisure time

Woman returns to dialysis after doctors remove transplanted pig kidney

Kaiser's Risant Health gobbled up Geisinger. Who is next?

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Intellia reports positive results for its CRISPR

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

See how much Covid

knowledge

focus

Wikipedia

leisure time